Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
[HTML][HTML] Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized …
…, B Li, Y Song, J Feng, J Li, Z He, R Zhou, W Li… - Journal of Thoracic …, 2020 - Elsevier
Introduction Sintilimab, an anti–programmed death 1 antibody, plus pemetrexed and
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer
J He, Y Hu, M Hu, B Li - Scientific reports, 2015 - nature.com
Lung cancer is currently the leading cause of cancer-related death in worldwide, non-small
cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum-…
cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum-…
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised …
…, W Yao, Q Wang, X Min, G Chen, X Xu, X Li… - The Lancet …, 2022 - thelancet.com
Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in …
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in …
[HTML][HTML] Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase …
…, J Zhou, C Zhou, B Li, J Li, M Fan, J Cui, Y Li… - Journal of Thoracic …, 2021 - Elsevier
Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum
plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus …
plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus …
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on …
…, L Han, L Miao, C Ding, J Cui, B Li, Y Pan, X Li… - The Lancet …, 2022 - thelancet.com
Background VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite
high initial response rates, almost all patients eventually develop treatment resistance to …
high initial response rates, almost all patients eventually develop treatment resistance to …
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess the …
tumour angiogenesis and proliferative signalling. The objective of this study was to assess the …
[HTML][HTML] AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with …
…, J Lu, S Chen, D Lv, G Zhang, C Liu, J Li… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …
The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA
J Li, Y Han, H Zhang, Z Qian, W Jia, Y Gao… - Biochemical and …, 2019 - Elsevier
Lung cancer is one of the leading causes of cancer-related death in developed countries.
Despite decades of intensive efforts to comate this malignant disease, the prognosis of lung …
Despite decades of intensive efforts to comate this malignant disease, the prognosis of lung …
[HTML][HTML] Toripalimab plus chemotherapy for patients with treatment-naive advanced non–small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)
Z Wang, L Wu, B Li, Y Cheng, X Li, X Wang… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
… Provision of study materials or patients: Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng,
Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv …
Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv …
